Search - tctmd.com

Displaying 41 - 60 of 82

Sort: Relevancy | Date

News Daily News

Ticagrelor Monotherapy After Multivessel PCI? Latest Slice From GLOBAL LEADERS Says . . . Maybe

Yael L. Maxwell

October 16, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Todd Neale

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

Presentation TCT 2019

STOPDAPT, SMART-CHOICE, and TWILIGHT: Will These Trials Change Your Clinical Practice?

Presenter: Aditya Kapoor

September 28, 2019

Presentation TCT 2019

Is it TWILIGHT for Aspirin? Critical Appraisal and Interpretation of the Trial

Presenter: Pascal Vranckx

September 28, 2019

Presentation TCT 2019

GLOBAL LEADERS: Ticagrelor Monotherapy vs. DAPT After PCI in TWILIGHT-Like Patients

Presenter: Yoshinobu Onuma

September 27, 2019

Presentation TCT 2019

Final Words

Presenter: Roxana Mehran

September 26, 2019

Presentation TCT 2019

Take Home for Clinicians: DM and STEMI

Presenter: Dominick Angiolillo

September 26, 2019

Presentation TCT 2019

COMPLETE Trial: Focus on STEMI and MVD

Presenter: Shamir Mehta

September 26, 2019

Presentation TCT 2019

The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease

Presenter: Marc Bonaca

September 26, 2019

Presentation TCT 2019

Take Home for Clinicians

Presenter: C. Michael Gibson

September 26, 2019

Presentation TCT 2019

Reconciling Adjudicated Data Within a Global Trial

Presenter: Marco Valgimigli

September 26, 2019

Presentation TCT 2019

Transitioning to Monotherapy in Patients After PCI

Presenter: Pascal Vranckx

September 26, 2019

Presentation TCT 2019

TWILIGHT: A Deep Dive

Presenter: Usman Baber

September 26, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

Presentation TCT 2019

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Presenter: Usman Baber

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

Presentation TCT 2019

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Presenter: Roxana Mehran

September 26, 2019

Advertisement

Ticagrelor Monotherapy After Multivessel PCI? Latest Slice From GLOBAL LEADERS Says . . . Maybe

TCTMD’s Top 10 Most Popular Stories for September 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

STOPDAPT, SMART-CHOICE, and TWILIGHT: Will These Trials Change Your Clinical Practice?

Is it TWILIGHT for Aspirin? Critical Appraisal and Interpretation of the Trial

GLOBAL LEADERS: Ticagrelor Monotherapy vs. DAPT After PCI in TWILIGHT-Like Patients

Final Words

Take Home for Clinicians: DM and STEMI

COMPLETE Trial: Focus on STEMI and MVD

The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease

Take Home for Clinicians

Reconciling Adjudicated Data Within a Global Trial

Transitioning to Monotherapy in Patients After PCI

TWILIGHT: A Deep Dive

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content